Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
暂无分享,去创建一个
[1] C. Papavassilis,et al. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis , 2020, The Journal of dermatological treatment.
[2] B. Strober,et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. , 2019, Journal of the American Academy of Dermatology.
[3] M. Gooderham,et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] M. Lebwohl,et al. Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks , 2019, The British journal of dermatology.
[5] A. Kimball,et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials , 2017, The Lancet.
[6] D. M. van der Heijde,et al. Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis , 2017, Arthritis care & research.
[7] C. Griffiths,et al. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis , 2017, The Journal of dermatological treatment.
[8] L. Puig,et al. PASI90 response: the new standard in therapeutic efficacy for psoriasis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] J. Erickson,et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate‐to‐severe plaque psoriasis , 2013, The British journal of dermatology.